Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

XERS

HOLD

Xeris Biopharma Holdings, Inc. · Healthcare · United States · $1.4B · Avg Vol: $18M/d

58
StockRank
Get insider-trade alerts
Q
67
V
20
M
64
P/E (TTM)
122.9x
ROE
4.0%
D/E
19.9x
Dividend %
—
Dir. Trades · 180d
−$2M →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company leveraging its proprietary XeriSol and XeriJect formulation technologies to develop ready-to-use liquid injectables. These platforms eliminate the need for reconstitution, offering a distinct competitive advantage in patient convenience and adherence. The company operates as a niche player focused on endocrine, metabolic, and neurological conditions.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue110.2M163.9M203.1M291.8M38.3%314.9M385.9M472.4M27.2%
EPS-0.70-0.45-0.370.00—0.07———
Shares136.3M138.1M149.4M166.2M+22.0%172.6M———
Debt198.1M229.2M271.4M258.1M9.2%258.6M———
Equity45.2M-6.8M-29.6M13.7M-32.8%————
Op CF-102.9M-47.0M-37.0M28.6M—48.5M———
Inv CF34.5M-6.0M4.9M-0.7M—————
Fin CF127.5M-1.6M36.2M11.4M—————
Loading 1Y...
PRICE (1Y)+20.9%
6.797.337.868.408.94Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$8.21
RSI (14)
47.4
52W High
$10.08
From 52W High
0.8%

SCORE BREAKDOWN

Quality
67
ROIC
10.8%76.3
ROE
4.0%54.8
GP/Assets
70.5%95.0
Op. Margin
9.5%65.5
FCF/Assets
11.0%89.2
Piotroski
893.2
Int. Cover
1.0x40.0
D/E Ratio
19.87x0.3
Current Ratio
2.12x39.8
Value
20
P/E (TTM)
122.9x7.6
EV/EBITDA
33.9x16.8
P/FCF
34.0x36.2
P/B
104.9x0.7
P/S
4.7x43.3
Div Yield
—N/A
Momentum
64
52W High %
81%72.6
RS 6M
0%73.4
SMA 50/200
1.02x69.9
EPS Rev 4W
-0.6%31.7
EPS Rev 12W
—N/A
EPS Improve
+461%95.7
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$1.4B
P/E (Forward)
21.9x
Gross Margin
85.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XERS are excluded.

TickerCompanyMkt CapStockRankSignal
XERSXeris Biopharma Holdings, Inc.(you)$1.4B58HOLD
ETONEton Pharmaceuticals, Inc.$1.2B62HOLD
CURA.TOCuraleaf Holdings, Inc.$2.5B51HOLD
SUPNSupernus Pharmaceuticals, Inc.$2.7B64HOLD
PAHCPhibro Animal Health Corporation$1.4B76BUY
HROWHarrow, Inc.$1.5B35SELL
AMPHAmphastar Pharmaceuticals, Inc.$825M75BUY
GLASGlass House Brands Inc.$899M35HOLD
TRLVTrulieve Cannabis Corp.$1.6B87STRONG BUY
PBHPrestige Consumer Healthcare Inc.$2.4B82STRONG BUY

Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%

Xeris Biopharma Holdings, Inc. (XERS) — Stock Score Summary

Xeris Biopharma Holdings, Inc. (XERS) has a MoatMap StockRank of 58/100 based on Quality (67/100), Value (20/100), and Momentum (64/100) factor scores. The current signal is HOLD.

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company leveraging its proprietary XeriSol and XeriJect formulation technologies to develop ready-to-use liquid injectables. These platforms eliminate the need for reconstitution, offering a distinct competitive advantage in patient convenience and adherence. The company operates as a niche player focused on endocrine, metabolic, and neurological conditions.

Key Financial Metrics

Price$8.21
Market Cap$1.4B
P/E (TTM)122.86
P/E (Forward)21.91
Price/Book104.88
Return on Equity4.0%
Return on Invested Capital10.8%
Debt/Equity19.87x
Gross Margin85.9%
Operating Margin9.5%
Revenue Growth38.3%
Free Cash Flow$42M

Xeris Biopharma Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Xeris Biopharma Holdings, Inc.’s (XERS) StockRank?
MoatMap’s StockRank for Xeris Biopharma Holdings, Inc. (XERS) is 58/100, with a Hold signal. It is a composite of Quality (67), Value (20), and Momentum (64) factor ranks across MoatMap’s 20,000+ stock universe.
Does Xeris Biopharma Holdings, Inc. have an economic moat?
Xeris Biopharma Holdings, Inc. (XERS) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Xeris Biopharma Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Xeris Biopharma Holdings, Inc. (XERS) is Hold, based on a StockRank of 58/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Xeris Biopharma Holdings, Inc. in?
Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksXERS deep dive reportAI ChampionsHow we score stocksSense-check another stock